Experimental evidence of a cyclopropylcarbinyl conjugative electronic effect.

Bicyclo[3.2.0]hept-2-enes undergo thermal rearrangement to norbornenes via diradical transition structures.

A vinylcyclobutane substrate designed as a cyclopropylcarbinyl radical probe.

Appending a spirocyclopropane linkage to bicyclo[3.2.0]hept-2-ene is achieved by selective kinetic cyclopropanation of 6-methylenebicyclo[3.

Thermal isomerizations of cis,anti,cis-tricyclo[7.4.0.0(2,8)]tridec-10-ene.

cis,anti,cis-Tricyclo[7.4.0.

Assessing onset of treatment benefit in depression and anxiety: conceptual considerations.

Objective: Methods for characterizing the onset of treatment benefit in major depressive disorder and generalized anxiety disorder have been studied for some time, yet there is no universal agreement as to the best approaches. Our purpose is to summarize the conceptual framework underlying modern methods for characterizing onset and detailed approaches for which there is consensus from the perspective of a clinician, clinical researcher, and statistician. Possible alternatives to unresolved issues are discussed.

Molecular rearrangements through thermal [1,3] carbon shifts.

Molecular rearrangements through thermal [1,3] carbon shifts, such as vinylcyclopropane-to-cyclopentene and vinylcyclobutane-to-cyclohexene isomerizations, were recognized and exemplified repeatedly from 1960-1964. Serious mechanistic studies of these and related rearrangements over the past 40 years have provided ample grounds for interpreting them as processes taking place by way of conformationally flexible but not statistically equilibrated diradical intermediates. Orbital symmetry theory fails to account for the stereochemical characteristics of [1,3] carbon shifts.

Effect of a methoxy substituent on the vinylcyclobutane carbon migration.

Over the temperature range 250-300 degrees C, 8-exo-methoxybicyclo[4.2.0]oct-2-ene (1a) undergoes a [1,3] sigmatropic rearrangement to 5-exo- and 5-endo-methoxybicyclo[2.

Thermal chemistry of bicyclo[4.2.0]oct-2-enes.

At 300 degrees C, bicyclo[4.2.0]oct-2-ene (1) isomerizes to bicyclo[2.

Thermal reactions of 7-d- and 8-d-bicyclo[4.2.0]oct-2-enes.

The gas phase thermal reactions exhibited by bicyclo[4.2.0]oct-2-ene and 7-d and 8-d analogues at 300 degrees C have been followed kinetically through GC and 2H NMR spectroscopic analyses.

Thermal isomerization of cis,anti,cis-tricyclo[6.3.0.0(2,7)]undec-3-ene to endo-tricyclo[5.2.2.0(2,6)]undec-8-ene.

[reaction: see text] The gas-phase thermal isomerization of cis,anti,cis-tricyclo[6.3.0.

Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes.

[reaction: see text] At 275 degrees C, 8-exo-methylbicyclo[4.2.0]oct-2-ene (1a) undergoes a [1,3] sigmatropic rearrangement to 5-methylbicyclo[2.

Deuterium kinetic isotope effects and mechanism of the thermal isomerization of bicyclo[4.2.0]oct-7-ene to 1,3-cyclooctadiene.

The thermal conversion of cis-bicyclo[4.2.0]oct-7-ene to cis,cis-1,3-cyclooctadiene might involve a direct disrotatory ring opening, or it might possibly take place by way of cis,trans-1,3-cyclooctadiene.

Thermal disrotatory electrocyclic isomerization of cis-bicyclo[4.2.0]oct-7-ene to cis,cis-1,3-cyclooctadiene.

[reaction: see text] The ratio of observed rate constants, k/k', for thermal isomerizations of cis-bicyclo[4.2.0]oct-7-ene and its 2,2,5,5-d(4) analogue to cis,cis-1,3-cyclooctadienes at 250 degrees C is 1.

Thermal [1,3] carbon sigmatropic rearrangements of vinylcyclobutanes.

Stereochemical, kinetic, and theory-based studies of the [1,3] carbon sigmatropic rearrangements of bicyclo[2.1.1]hex-2-enes, bicyclo[3.

Thermal rearrangement of 7-methylbicyclo.

The gas-phase thermal rearrangement of exo-7-methylbicyclo[3.2.0]hept-2-ene yields almost exclusively 5-methylnorbornene products.

The use of placebo control groups in the assessment of psychiatric drugs: an historical context.

The reliable evaluation of treatments intended for the management of psychiatric illness would not be possible without the use of placebo. Other types of control groups can provide useful information, but none are capable of adducing a finding as compelling and unambiguously interpretable as a statistically significant drug-placebo difference. Its epistemological advantage notwithstanding, the ethicality of employing a placebo control group has been increasingly challenged in recent years.

Threats to the validity of clinical trials employing enrichment strategies for sample selection.

Subject selection and exclusion criteria employed in typical clinical effectiveness trials of investigational new drugs have two fundamental aims: (1) to ensure that patients entering a study are truly suffering from the condition the drug is intended to treat and (2) to maximize the likelihood that the study will detect an effect of the drug if, in fact, one exists. Typical protocol selection criteria not only specify exacting procedures for establishing and documenting the diagnosis of those recruited for a study but also seek to increase, relative to the prevalence in the general population, the proportion of individuals in the sample likely to respond to pharmacological treatment. Because it is ordinarily impossible to learn prior to extensive clinical experience with a new drug which, if any, patient characteristics reliably predict a consistent treatment response, strategies for sample "enrichment" typically operate by excluding patients (for example, those with very advanced and/or complicated illness, those with serious concomitant illness, those at the extremes of age, those with very mild illness, and so forth) in whom a dependable response to treatment seems unlikely on logical and/or generic grounds.

Slowing the progression of Alzheimer disease: methodologic issues.

The evidence to support a claim that a new drug will slow the progression of Alzheimer disease (AD) must derive from epistemologically valid research methods. Although agency regulations do not specify the magnitude of an effect that a drug must possess to be granted a claim as a treatment for AD, the evidence to support any claim must be adduced in adequate and well-controlled clinical investigations and must meet the standard of "substantial evidence." Because a claim presented in drug product labeling may not be false or misleading in any particular, a distinction must be made between treatments that provide a "symptomatic" benefit and those that alter the course of dementia.

Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group.

Two suggested clinical trial designs for assessing progression of Alzheimer disease are the randomized withdrawal design and the randomized start design. The most promising of these, the randomized start design, has the potential to demonstrate a delay in progression, but there remain problematic design, ethical, and statistical issues to be solved before the protocol can be used in a clinical trial. The development of biological markers of the disease process using neuroimaging or other measures also may provide a robust method of measuring disease progression and demonstrating the biological effect of a drug on the disease process.